let details = [ 
{ id: "0", PMID: "20113659", Title: "[Urinary leukotrience E(4) level in children with asthma].", Abstract: "[{'@Label': 'OBJECTIVE', '@NlmCategory': 'OBJECTIVE', '#text': 'Cysteinyl leukotriene (CysLTs) plays an important role in airway inflammation and remodeling in asthma. Measurement of urinary leukotriene E(4) (LTE(4)) is a sensitive and noninvasive method of assaying total body CysLTs level. This study aimed to evaluate the clinical significance of urinary leukotriene E(4) (LTE(4)) in childhood asthma.'}, {'@Label': 'METHODS', '@NlmCategory': 'METHODS', '#text': 'Sixty children with acute asthma were randomly divided into montelukast (leukotriene receptor antagonist) treatment and conventional treatment groups (n = 30 each). Urinary LTE(4) levels were measured using ELISA and the airway resistance Rint was assessed by the lung function instrument at the acute and the convalescence phases. Twenty healthy children were used as the control group.'}, {'@Label': 'RESULTS', '@NlmCategory': 'RESULTS', '#text': 'Urinary LTE(4) levels in asthmatic children at the acute and the convalescence phases were significantly higher than those in the control group (p<0.01). The urinary LTE(4) levels at the convalescence phase were significantly reduced compared with those at the acute phase in asthmatic children (p<0.01). More significantly decreased urinary LTE(4) levels were noted in the montelukast treatment group than the conventional treatment group at the convalescence phase (p<0.01). In the acute phase, there was no correlation between urinary LTE4 level and Rint in asthmatic children.'}, {'@Label': 'CONCLUSIONS', '@NlmCategory': 'CONCLUSIONS', '#text': 'Urinary LTE(4) level is significantly increased in children with acute asthma. Urinary LTE(4) is a useful marker for the diagnosis of asthma and can be as a predictor of asthma control and marker of susceptibility to treatment with leukotriene receptor antagonists.'}]", AuthorList: "{'@CompleteYN': 'Y', 'Author': [{'@ValidYN': 'Y', 'LastName': 'He', 'ForeName': 'Mei-Juan', 'Initials': 'MJ', 'AffiliationInfo': {'Affiliation': 'Department of Respiratory Medicine, Jiangxi Children's Hospital, Nanchang 330006, China.'}}, {'@ValidYN': 'Y', 'LastName': 'Chen', 'ForeName': 'Qiang', 'Initials': 'Q'}, {'@ValidYN': 'Y', 'LastName': 'Liu', 'ForeName': 'Jian-Mei', 'Initials': 'JM'}]}", Journal: "Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics",PublicationYear: "2009", MeSHTerms: "{'MeshHeading': [{'DescriptorName': {'@UI': 'D000403', '@MajorTopicYN': 'N', '#text': 'Airway Resistance'}}, {'DescriptorName': {'@UI': 'D001249', '@MajorTopicYN': 'N', '#text': 'Asthma'}, 'QualifierName': [{'@UI': 'Q000175', '@MajorTopicYN': 'N', '#text': 'diagnosis'}, {'@UI': 'Q000503', '@MajorTopicYN': 'N', '#text': 'physiopathology'}, {'@UI': 'Q000652', '@MajorTopicYN': 'Y', '#text': 'urine'}]}, {'DescriptorName': {'@UI': 'D002675', '@MajorTopicYN': 'N', '#text': 'Child, Preschool'}}, {'DescriptorName': {'@UI': 'D004797', '@MajorTopicYN': 'N', '#text': 'Enzyme-Linked Immunosorbent Assay'}}, {'DescriptorName': {'@UI': 'D005260', '@MajorTopicYN': 'N', '#text': 'Female'}}, {'DescriptorName': {'@UI': 'D006801', '@MajorTopicYN': 'N', '#text': 'Humans'}}, {'DescriptorName': {'@UI': 'D007223', '@MajorTopicYN': 'N', '#text': 'Infant'}}, {'DescriptorName': {'@UI': 'D017999', '@MajorTopicYN': 'N', '#text': 'Leukotriene E4'}, 'QualifierName': {'@UI': 'Q000652', '@MajorTopicYN': 'Y', '#text': 'urine'}}, {'DescriptorName': {'@UI': 'D008297', '@MajorTopicYN': 'N', '#text': 'Male'}}]}", Pagination: "{'StartPage': '909', 'EndPage': '912', 'MedlinePgn': '909-12'}", ExternalLink: "https://pubmed.ncbi.nlm.nih.gov/20113659/"},
{ id: "1", PMID: "20074456", Title: "GGTI-2133, an inhibitor of geranylgeranyltransferase, inhibits infiltration of inflammatory cells into airways in mouse experimental asthma.", Abstract: "Statins have been proposed as a novel treatment of respiratory diseases including asthma. Although the mechanism of anti-inflammatory effect of statins is still unclear, an inhibition of protein prenylation by depleting the downstream metabolites of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase might be involved. To test the hypothesis, the effects of GGTI-2133, a direct inhibitor of geran ylgeranyltransferase (GGTase), on antigen-induced airway inflammation were investigated in a murine model of allergic bronchial asthma. Mice were sensitized and repeatedly challenged with ovalbumin antigen (OA). Animals were also treated with GGTI-2133 (5 mg/kg/day, i.p.) once a day before and during the antigen inhalation period. Repeated antigen inhalation caused an infiltration of inflammatory cells, especially eosinophils, into airways. Significant increases in interleukin (IL)-4, IL-13, eotaxin, thymus and activation-regulated chemokine (TARC) and leukotriene B4 (LTB4) in bronchoalveolar lavage fluids and total and OA-specific IgE in sera were also found in the antigen-exposed animals. The systemic treatments with GGTI-2133 inhibited the antigen-induced eosinophil infiltration into airways almost completely. However, interestingly, the GGTI-2133 treatment did not affect the levels of these chemotactic factors and IgE. These findings suggest that selective inhibition of GGTase is effective for eosinophilic airway inflammation such as asthma.", AuthorList: "{'@CompleteYN': 'Y', 'Author': [{'@ValidYN': 'Y', 'LastName': 'Chiba', 'ForeName': 'Y', 'Initials': 'Y', 'AffiliationInfo': {'Affiliation': 'Department of Pharmacology, School of Pharmacy, Hoshi University, Tokyo, Japan. chiba@hoshi.ac.jp'}}, {'@ValidYN': 'Y', 'LastName': 'Sato', 'ForeName': 'S', 'Initials': 'S'}, {'@ValidYN': 'Y', 'LastName': 'Misawa', 'ForeName': 'M', 'Initials': 'M'}]}", Journal: "International journal of immunopathology and pharmacology",PublicationYear: "2009", MeSHTerms: "{'MeshHeading': [{'DescriptorName': {'@UI': 'D019883', '@MajorTopicYN': 'N', '#text': 'Alkyl and Aryl Transferases'}, 'QualifierName': [{'@UI': 'Q000037', '@MajorTopicYN': 'Y', '#text': 'antagonists & inhibitors'}, {'@UI': 'Q000378', '@MajorTopicYN': 'N', '#text': 'metabolism'}]}, {'DescriptorName': {'@UI': 'D000818', '@MajorTopicYN': 'N', '#text': 'Animals'}}, {'DescriptorName': {'@UI': 'D018927', '@MajorTopicYN': 'N', '#text': 'Anti-Asthmatic Agents'}, 'QualifierName': [{'@UI': 'Q000008', '@MajorTopicYN': 'N', '#text': 'administration & dosage'}, {'@UI': 'Q000494', '@MajorTopicYN': 'Y', '#text': 'pharmacology'}]}, {'DescriptorName': {'@UI': 'D001249', '@MajorTopicYN': 'N', '#text': 'Asthma'}, 'QualifierName': [{'@UI': 'Q000188', '@MajorTopicYN': 'Y', '#text': 'drug therapy'}, {'@UI': 'Q000201', '@MajorTopicYN': 'N', '#text': 'enzymology'}, {'@UI': 'Q000276', '@MajorTopicYN': 'N', '#text': 'immunology'}]}, {'DescriptorName': {'@UI': 'D001992', '@MajorTopicYN': 'N', '#text': 'Bronchoalveolar Lavage Fluid'}, 'QualifierName': [{'@UI': 'Q000166', '@MajorTopicYN': 'N', '#text': 'cytology'}, {'@UI': 'Q000276', '@MajorTopicYN': 'N', '#text': 'immunology'}]}, {'DescriptorName': {'@UI': 'D054414', '@MajorTopicYN': 'N', '#text': 'Chemokine CCL17'}, 'QualifierName': {'@UI': 'Q000378', '@MajorTopicYN': 'N', '#text': 'metabolism'}}, {'DescriptorName': {'@UI': 'D004195', '@MajorTopicYN': 'N', '#text': 'Disease Models, Animal'}}, {'DescriptorName': {'@UI': 'D004791', '@MajorTopicYN': 'N', '#text': 'Enzyme Inhibitors'}, 'QualifierName': {'@UI': 'Q000494', '@MajorTopicYN': 'Y', '#text': 'pharmacology'}}, {'DescriptorName': {'@UI': 'D007093', '@MajorTopicYN': 'N', '#text': 'Imidazoles'}, 'QualifierName': [{'@UI': 'Q000008', '@MajorTopicYN': 'N', '#text': 'administration & dosage'}, {'@UI': 'Q000494', '@MajorTopicYN': 'Y', '#text': 'pharmacology'}]}, {'DescriptorName': {'@UI': 'D007073', '@MajorTopicYN': 'N', '#text': 'Immunoglobulin E'}, 'QualifierName': {'@UI': 'Q000097', '@MajorTopicYN': 'N', '#text': 'blood'}}, {'DescriptorName': {'@UI': 'D007274', '@MajorTopicYN': 'N', '#text': 'Injections, Intraperitoneal'}}, {'DescriptorName': {'@UI': 'D018793', '@MajorTopicYN': 'N', '#text': 'Interleukin-13'}, 'QualifierName': {'@UI': 'Q000378', '@MajorTopicYN': 'N', '#text': 'metabolism'}}, {'DescriptorName': {'@UI': 'D015847', '@MajorTopicYN': 'N', '#text': 'Interleukin-4'}, 'QualifierName': {'@UI': 'Q000378', '@MajorTopicYN': 'N', '#text': 'metabolism'}}, {'DescriptorName': {'@UI': 'D007930', '@MajorTopicYN': 'N', '#text': 'Leucine'}, 'QualifierName': [{'@UI': 'Q000008', '@MajorTopicYN': 'N', '#text': 'administration & dosage'}, {'@UI': 'Q000031', '@MajorTopicYN': 'Y', '#text': 'analogs & derivatives'}, {'@UI': 'Q000494', '@MajorTopicYN': 'N', '#text': 'pharmacology'}]}, {'DescriptorName': {'@UI': 'D007975', '@MajorTopicYN': 'N', '#text': 'Leukotriene B4'}, 'QualifierName': {'@UI': 'Q000378', '@MajorTopicYN': 'N', '#text': 'metabolism'}}, {'DescriptorName': {'@UI': 'D008297', '@MajorTopicYN': 'N', '#text': 'Male'}}, {'DescriptorName': {'@UI': 'D051379', '@MajorTopicYN': 'N', '#text': 'Mice'}}, {'DescriptorName': {'@UI': 'D008807', '@MajorTopicYN': 'N', '#text': 'Mice, Inbred BALB C'}}, {'DescriptorName': {'@UI': 'D009281', '@MajorTopicYN': 'N', '#text': 'Naphthalenes'}, 'QualifierName': [{'@UI': 'Q000008', '@MajorTopicYN': 'N', '#text': 'administration & dosage'}, {'@UI': 'Q000494', '@MajorTopicYN': 'Y', '#text': 'pharmacology'}]}, {'DescriptorName': {'@UI': 'D010047', '@MajorTopicYN': 'N', '#text': 'Ovalbumin'}}, {'DescriptorName': {'@UI': 'D017368', '@MajorTopicYN': 'N', '#text': 'Protein Prenylation'}}, {'DescriptorName': {'@UI': 'D011657', '@MajorTopicYN': 'N', '#text': 'Pulmonary Eosinophilia'}, 'QualifierName': [{'@UI': 'Q000201', '@MajorTopicYN': 'N', '#text': 'enzymology'}, {'@UI': 'Q000276', '@MajorTopicYN': 'N', '#text': 'immunology'}, {'@UI': 'Q000517', '@MajorTopicYN': 'Y', '#text': 'prevention & control'}]}]}", Pagination: "{'StartPage': '929', 'EndPage': '935', 'MedlinePgn': '929-35'}", ExternalLink: "https://pubmed.ncbi.nlm.nih.gov/20074456/"},
{ id: "2", PMID: "20046412", Title: "Update on recent advances in the management of aspirin exacerbated respiratory disease.", Abstract: "Aspirin intolerant asthma (AIA) is frequently characterized as an aspirin (ASA)-exacerbated respiratory disease (AERD). It is a clinical syndrome associated with chronic severe inflammation in the upper and lower airways resulting in chronic rhinitis, sinusitis, recurrent polyposis, and asthma. AERD generally develops secondary to abnormalities in inflammatory mediators and arachidonic acid biosynthesis expression. Upper and lower airway eosinophil infiltration is a key feature of AERD; however, the exact mechanisms of such chronic eosinophilic inflammation are not fully understood. Cysteinyl leukotriene over-production may be a key factor in the induction of eosinophilic activation. Genetic studies have suggested a role for variability of genes in disease susceptibility and response to medication. Potential genetic biomarkers contributing to the AERD phenotype include HLA-DPB1*301, LTC4S, ALOX5, CYSLT, PGE2, TBXA2R, TBX21, MS4A2, IL10 -1082A > G, ACE -262A > T, and CRTH2 -466T > C; the four-locus SNP set was composed of B2ADR 46A > G, CCR3 -520T > G, CysLTR1 -634C > T, and FCER1B -109T > C. Management of AERD is an important issue. Aspirin ingestion may result in significant morbidity and mortality, and patients must be advised regarding aspirin risk. Leukotriene receptor antagonists (LTRA) that inhibit leukotriene pathways have an established role in long-term AERD management and rhinosinusitis. Aspirin desensitization may be required for the relief of upper and lower airway symptoms in AERD patients. Future research should focus on identification of biomarkers for a comprehensive diagnostic approach.", AuthorList: "{'@CompleteYN': 'Y', 'Author': [{'@ValidYN': 'Y', 'LastName': 'Palikhe', 'ForeName': 'Nami Shrestha', 'Initials': 'NS', 'AffiliationInfo': {'Affiliation': 'Department of Allergy and Rheumatology, Ajou University School of Medicine, Yeongtong-gu, Suwon, Korea.'}}, {'@ValidYN': 'Y', 'LastName': 'Kim', 'ForeName': 'Joo-Hee', 'Initials': 'JH'}, {'@ValidYN': 'Y', 'LastName': 'Park', 'ForeName': 'Hae-Sim', 'Initials': 'HS'}]}", Journal: "Yonsei medical journal",PublicationYear: "2009", MeSHTerms: "{'MeshHeading': [{'DescriptorName': {'@UI': 'D000818', '@MajorTopicYN': 'N', '#text': 'Animals'}}, {'DescriptorName': {'@UI': 'D055963', '@MajorTopicYN': 'N', '#text': 'Asthma, Aspirin-Induced'}, 'QualifierName': [{'@UI': 'Q000188', '@MajorTopicYN': 'N', '#text': 'drug therapy'}, {'@UI': 'Q000235', '@MajorTopicYN': 'Y', '#text': 'genetics'}, {'@UI': 'Q000276', '@MajorTopicYN': 'Y', '#text': 'immunology'}]}, {'DescriptorName': {'@UI': 'D004804', '@MajorTopicYN': 'N', '#text': 'Eosinophils'}, 'QualifierName': {'@UI': 'Q000378', '@MajorTopicYN': 'N', '#text': 'metabolism'}}, {'DescriptorName': {'@UI': 'D020022', '@MajorTopicYN': 'N', '#text': 'Genetic Predisposition to Disease'}, 'QualifierName': {'@UI': 'Q000235', '@MajorTopicYN': 'N', '#text': 'genetics'}}, {'DescriptorName': {'@UI': 'D006801', '@MajorTopicYN': 'N', '#text': 'Humans'}}, {'DescriptorName': {'@UI': 'D020024', '@MajorTopicYN': 'N', '#text': 'Leukotriene Antagonists'}, 'QualifierName': {'@UI': 'Q000627', '@MajorTopicYN': 'N', '#text': 'therapeutic use'}}, {'DescriptorName': {'@UI': 'D015289', '@MajorTopicYN': 'N', '#text': 'Leukotrienes'}, 'QualifierName': {'@UI': 'Q000378', '@MajorTopicYN': 'N', '#text': 'metabolism'}}, {'DescriptorName': {'@UI': 'D008954', '@MajorTopicYN': 'N', '#text': 'Models, Biological'}}, {'DescriptorName': {'@UI': 'D011110', '@MajorTopicYN': 'N', '#text': 'Polymorphism, Genetic'}, 'QualifierName': [{'@UI': 'Q000235', '@MajorTopicYN': 'N', '#text': 'genetics'}, {'@UI': 'Q000502', '@MajorTopicYN': 'N', '#text': 'physiology'}]}]}", Pagination: "{'StartPage': '744', 'EndPage': '750', 'MedlinePgn': '744-50'}", ExternalLink: "https://pubmed.ncbi.nlm.nih.gov/20046412/"},
];
export default details;